CDK2 and carcinoma: In 2017, Ammar et al. [29] synthesized isatin-linked chalcone analogues (Figure 3a) with an aim to investigate the cyclin-dependent kinase 2 (CDK2) inhibitory properties and cytotoxic potency against human carcinoma cell lines HepG-2, MCF-7, HCT-116, and the MCF-12A breast cell line.